{"id":145737,"date":"2013-09-06T15:17:50","date_gmt":"2013-09-06T19:17:50","guid":{"rendered":"\/gazette\/?p=145737"},"modified":"2019-04-03T15:12:21","modified_gmt":"2019-04-03T19:12:21","slug":"cancer-vaccine-begins-phase-i-clinical-trials","status":"publish","type":"post","link":"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/","title":{"rendered":"Cancer vaccine begins Phase I clinical trials"},"content":{"rendered":"<header\n\tclass=\"wp-block-harvard-gazette-article-header alignfull article-header is-style-full-width-text-below centered-image\"\n\tstyle=\" \"\n>\n\t<figure class=\"wp-block-video\">\r\n<span class=\"embed-youtube\" style=\"text-align:center; display: block;\"><iframe loading=\"lazy\" class=\"youtube-player\" width=\"640\" height=\"360\" src=\"https:\/\/www.youtube.com\/embed\/VsNmSSLBXs8?version=3&#038;rel=1&#038;showsearch=0&#038;showinfo=1&#038;iv_load_policy=1&#038;fs=1&#038;hl=en-US&#038;autohide=2&#038;wmode=transparent\" allowfullscreen=\"true\" style=\"border:0;\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-presentation allow-popups-to-escape-sandbox\"><\/iframe><\/span>\r\n<figcaption class=\"wp-element-caption\"><p class=\"wp-element-caption--credit\">The Wyss Institute<\/p><\/figcaption><\/figure>\n\n\t<div class=\"article-header__content\">\n\t\t\t<a\n\t\t\tclass=\"article-header__category\"\n\t\t\thref=\"https:\/\/news.harvard.edu\/gazette\/section\/health\/\"\n\t\t>\n\t\t\tHealth\t\t<\/a>\n\t\t\n\t\t<h1 class=\"article-header__title wp-block-heading \">\n\t\tCancer vaccine begins Phase I clinical trials\t<\/h1>\n\n\t\n\t\t\t<\/div>\n\t\t\n\t<div class=\"article-header__meta\">\n\t\t<div class=\"wp-block-post-author\">\n\t\t\t<address class=\"wp-block-post-author__content\">\n\t\t\t\t\t<p class=\"author wp-block-post-author__name\">\n\t\tDan Ferber\t<\/p>\n\t\t\t<p class=\"wp-block-post-author__byline\">\n\t\t\tWyss Institute Communications\t\t<\/p>\n\t\t\t\t\t<\/address>\n\t\t<\/div>\n\n\t\t<time class=\"article-header__date\" datetime=\"2013-09-06\">\n\t\t\tSeptember 6, 2013\t\t<\/time>\n\n\t\t<span class=\"article-header__reading-time\">\n\t\t\t4 min read\t\t<\/span>\n\t<\/div>\n\n\t\n\t\t\t<h2 class=\"article-header__subheading wp-block-heading\">\n\t\t\tDesigned to target skin cancer, implantable vaccine opens door to treating many cancers, inflammatory diseases\t\t<\/h2>\n\t\t\n<\/header>\n\n\n\n<div class=\"wp-block-group alignwide has-global-padding is-content-justification-center is-layout-constrained wp-block-group-is-layout-constrained\">\n\n\n\t\t<p>A cross-disciplinary team of Harvard scientists, engineers, and clinicians announced today that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer.<\/p>\n<p>The effort is the fruit of a new model of translational research being pursued at <a href=\"http:\/\/wyss.harvard.edu\/\">the Wyss Institute for Biologically Inspired Engineering at Harvard University<\/a> that integrates the latest cancer research with bioinspired technology development. It was led by Wyss core faculty member <a href=\"http:\/\/www.seas.harvard.edu\/directory\/mooneyd\">David J. Mooney<\/a>, who is also the Robert P. Pinkas Family Professor of Bioengineering at the <a href=\"http:\/\/www.seas.harvard.edu\/\">Harvard School of Engineering and Applied Sciences<\/a> (SEAS), and Wyss Institute associate faculty member Glenn Dranoff, who is co-leader of Dana-Farber Cancer Institute\u2019s Cancer Vaccine Center.<\/p>\n<p>Most therapeutic cancer vaccines available require doctors to first remove the patient\u2019s immune cells, then reprogram them and reintroduce them back into the body. The new approach, which was first reported to eliminate tumors in mice in <a href=\"http:\/\/stm.sciencemag.org\/\">Science Translational Medicine<\/a> in 2009, instead uses a disk-like sponge about the size of a fingernail that is made from FDA-approved polymers. The sponge is implanted under the skin, and is designed to recruit and reprogram a patient\u2019s own immune cells \u201con site,\u201d instructing them to travel through the body, home in on cancer cells, then kill them.<\/p>\n<p>The technology was initially designed to target cancerous cells in skin, but might have application to other cancers. In the preclinical study reported in Science Translational Medicine, 50 percent of mice treated with two doses of the vaccine \u2014 mice that would have otherwise died from melanoma within about 25 days \u2014 showed complete tumor regression.<\/p>\n<p>\u201cOur vaccine was made possible by combining a wide range of biomedical expertise that thrives in Boston and Cambridge,\u201d said Mooney, who specializes in the design of biomaterials for tissue engineering and drug delivery. \u201cIt reflects the bioinspired engineering savvy and technology development focus of engineers and scientists at the Wyss Institute and Harvard SEAS, as well as the immunological and clinical expertise of the researchers and clinicians at <a href=\"http:\/\/www.dana-farber.org\/\">Dana-Farber<\/a> and <a href=\"http:\/\/hms.harvard.edu\/\">Harvard Medical School<\/a>.\u201d<\/p>\n<p>\u201cThis is expected to be the first of many new innovative therapies made possible by the Wyss Institute\u2019s collaborative model of translational research that will enter human clinical trials,\u201d said Wyss\u2019 founding director, Don Ingber of <a href=\"http:\/\/www.childrenshospital.org\/\">Children\u2019s Hospital Boston<\/a>, who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and a professor of bioengineering at SEAS. \u201cIt validates our approach, which strives to move technologies into the clinical space much faster than would be possible in a traditional academic environment. It\u2019s enormously gratifying to see one of our first technologies take this giant leap forward.\u201d<\/p>\n<p>The Wyss Institute comprises a consortium of researchers, engineers, clinicians, and staff with industrial and business development experience from the Wyss Institute and nine other collaborating institutions in Greater Boston.<\/p>\n<p>\u201cIt is rare to get a new technology tested in the laboratory and moved into human clinical trials so quickly,\u201d said Dranoff, who is also a Professor of Medicine at Harvard Medical School, and leader of the Dana-Farber\/Harvard Cancer Center program in cancer immunology. \u201cWe\u2019re beyond thrilled with the momentum, and excited about its potential.\u201d<\/p>\n<p>The goal of the Phase I study, which is expected to conclude in 2015, is to assess the safety of the vaccine in humans.<\/p>\n<p>The cancer vaccine work has received support from the Wyss Institute, Dana-Farber, and the National Institutes of Health. In addition to Mooney, Dranoff, and Hodi, other collaborators include Wyss senior staff scientist Edward Doherty, Wyss staff scientist Omar Ali, Jerry Ritz, director of the Cell Processing Laboratory at Dana-Farber, Sara Russell, and Charles Yoon, surgeons at Dana-Farber, and other clinical research team members based at Dana-Farber.<\/p>\n<p><a href=\"http:\/\/wyss.harvard.edu\/viewpressrelease\/122\">To learn more.<\/a><\/p>\n\n\n<\/div>\n\n\t\t","protected":false},"excerpt":{"rendered":"<p>A cross-disciplinary team of Harvard scientists, engineers, and clinicians announced Sept. 6 that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer.<\/p>\n","protected":false},"author":105622744,"featured_media":146093,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"gz_ga_pageviews":27,"gz_ga_lastupdated":"2021-04-23 03:22","document_color_palette":"crimson","author":"Dan Ferber","affiliation":"Wyss Institute Communications","_category_override":"","_yoast_wpseo_primary_category":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[39644],"tags":[6998,7021,9744,10140,11266,15922,25571,26305,29171,30691,31448,36252,36253],"gazette-formats":[],"series":[],"class_list":["post-145737","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-cancer","tag-cancer-vaccine","tag-dana-farber-cancer-institute","tag-david-j-mooney","tag-donald-ingber","tag-harvard-medical-school","tag-news-hub","tag-one-harvard","tag-research","tag-science-translational-medicine","tag-skin-cancer","tag-wyss-institute","tag-wyss-institute-for-biologically-inspired-engineering"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.0 (Yoast SEO v27.1.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cancer vaccine begins Phase I clinical trials &#8212; Harvard Gazette<\/title>\n<meta name=\"description\" content=\"A cross-disciplinary team of Harvard scientists, engineers, and clinicians announced Sept. 6 that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cancer vaccine begins Phase I clinical trials &#8212; Harvard Gazette\" \/>\n<meta property=\"og:description\" content=\"A cross-disciplinary team of Harvard scientists, engineers, and clinicians announced Sept. 6 that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"Harvard Gazette\" \/>\n<meta property=\"article:published_time\" content=\"2013-09-06T19:17:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-04-03T19:12:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2013\/09\/cancervaccine605.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"605\" \/>\n\t<meta property=\"og:image:height\" content=\"403\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"harvardgazette\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/\"},\"author\":{\"name\":\"harvardgazette\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#\/schema\/person\/78d028cf624923e92682268709ffbc4b\"},\"headline\":\"Cancer vaccine begins Phase I clinical trials\",\"datePublished\":\"2013-09-06T19:17:50+00:00\",\"dateModified\":\"2019-04-03T19:12:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/\"},\"wordCount\":639,\"publisher\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#organization\"},\"image\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2013\/09\/cancervaccine605.jpg\",\"keywords\":[\"Cancer\",\"Cancer vaccine\",\"Dana-Farber Cancer Institute\",\"David J. Mooney\",\"Donald Ingber\",\"Harvard Medical School\",\"News Hub\",\"One Harvard\",\"Research\",\"Science Translational Medicine\",\"Skin Cancer\",\"Wyss Institute\",\"Wyss Institute for Biologically Inspired Engineering\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"copyrightYear\":\"2013\",\"copyrightHolder\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/\",\"url\":\"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/\",\"name\":\"Cancer vaccine begins Phase I clinical trials &#8212; Harvard Gazette\",\"isPartOf\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2013\/09\/cancervaccine605.jpg\",\"datePublished\":\"2013-09-06T19:17:50+00:00\",\"dateModified\":\"2019-04-03T19:12:21+00:00\",\"description\":\"A cross-disciplinary team of Harvard scientists, engineers, and clinicians announced Sept. 6 that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/#primaryimage\",\"url\":\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2013\/09\/cancervaccine605.jpg\",\"contentUrl\":\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2013\/09\/cancervaccine605.jpg\",\"width\":605,\"height\":403},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#website\",\"url\":\"https:\/\/news.harvard.edu\/gazette\/\",\"name\":\"Harvard Gazette\",\"description\":\"Official news from Harvard University covering innovation in teaching, learning, and research\",\"publisher\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/news.harvard.edu\/gazette\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#organization\",\"name\":\"The Harvard Gazette\",\"url\":\"https:\/\/news.harvard.edu\/gazette\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2023\/12\/Harvard_Gazette_logo.svg\",\"contentUrl\":\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2023\/12\/Harvard_Gazette_logo.svg\",\"width\":164,\"height\":64,\"caption\":\"The Harvard Gazette\"},\"image\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#\/schema\/person\/78d028cf624923e92682268709ffbc4b\",\"name\":\"harvardgazette\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cancer vaccine begins Phase I clinical trials &#8212; Harvard Gazette","description":"A cross-disciplinary team of Harvard scientists, engineers, and clinicians announced Sept. 6 that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/","og_locale":"en_US","og_type":"article","og_title":"Cancer vaccine begins Phase I clinical trials &#8212; Harvard Gazette","og_description":"A cross-disciplinary team of Harvard scientists, engineers, and clinicians announced Sept. 6 that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer.","og_url":"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/","og_site_name":"Harvard Gazette","article_published_time":"2013-09-06T19:17:50+00:00","article_modified_time":"2019-04-03T19:12:21+00:00","og_image":[{"width":605,"height":403,"url":"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2013\/09\/cancervaccine605.jpg","type":"image\/jpeg"}],"author":"harvardgazette","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/#article","isPartOf":{"@id":"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/"},"author":{"name":"harvardgazette","@id":"https:\/\/news.harvard.edu\/gazette\/#\/schema\/person\/78d028cf624923e92682268709ffbc4b"},"headline":"Cancer vaccine begins Phase I clinical trials","datePublished":"2013-09-06T19:17:50+00:00","dateModified":"2019-04-03T19:12:21+00:00","mainEntityOfPage":{"@id":"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/"},"wordCount":639,"publisher":{"@id":"https:\/\/news.harvard.edu\/gazette\/#organization"},"image":{"@id":"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2013\/09\/cancervaccine605.jpg","keywords":["Cancer","Cancer vaccine","Dana-Farber Cancer Institute","David J. Mooney","Donald Ingber","Harvard Medical School","News Hub","One Harvard","Research","Science Translational Medicine","Skin Cancer","Wyss Institute","Wyss Institute for Biologically Inspired Engineering"],"articleSection":["Health"],"inLanguage":"en-US","copyrightYear":"2013","copyrightHolder":{"@id":"https:\/\/news.harvard.edu\/gazette\/#organization"}},{"@type":"WebPage","@id":"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/","url":"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/","name":"Cancer vaccine begins Phase I clinical trials &#8212; Harvard Gazette","isPartOf":{"@id":"https:\/\/news.harvard.edu\/gazette\/#website"},"primaryImageOfPage":{"@id":"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/#primaryimage"},"image":{"@id":"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2013\/09\/cancervaccine605.jpg","datePublished":"2013-09-06T19:17:50+00:00","dateModified":"2019-04-03T19:12:21+00:00","description":"A cross-disciplinary team of Harvard scientists, engineers, and clinicians announced Sept. 6 that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/#primaryimage","url":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2013\/09\/cancervaccine605.jpg","contentUrl":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2013\/09\/cancervaccine605.jpg","width":605,"height":403},{"@type":"WebSite","@id":"https:\/\/news.harvard.edu\/gazette\/#website","url":"https:\/\/news.harvard.edu\/gazette\/","name":"Harvard Gazette","description":"Official news from Harvard University covering innovation in teaching, learning, and research","publisher":{"@id":"https:\/\/news.harvard.edu\/gazette\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/news.harvard.edu\/gazette\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/news.harvard.edu\/gazette\/#organization","name":"The Harvard Gazette","url":"https:\/\/news.harvard.edu\/gazette\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/news.harvard.edu\/gazette\/#\/schema\/logo\/image\/","url":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2023\/12\/Harvard_Gazette_logo.svg","contentUrl":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2023\/12\/Harvard_Gazette_logo.svg","width":164,"height":64,"caption":"The Harvard Gazette"},"image":{"@id":"https:\/\/news.harvard.edu\/gazette\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/news.harvard.edu\/gazette\/#\/schema\/person\/78d028cf624923e92682268709ffbc4b","name":"harvardgazette"}]}},"parsely":{"version":"1.1.0","canonical_url":"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/","smart_links":{"inbound":0,"outbound":0},"traffic_boost_suggestions_count":0,"meta":{"@context":"https:\/\/schema.org","@type":"NewsArticle","headline":"Cancer vaccine begins Phase I clinical trials","url":"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/","mainEntityOfPage":{"@type":"WebPage","@id":"https:\/\/news.harvard.edu\/gazette\/story\/2013\/09\/cancer-vaccine-begins-phase-i-clinical-trials\/"},"thumbnailUrl":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2013\/09\/cancervaccine605.jpg?w=150","image":{"@type":"ImageObject","url":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2013\/09\/cancervaccine605.jpg"},"articleSection":"Health","author":[{"@type":"Person","name":"harvardgazette"}],"creator":["harvardgazette"],"publisher":{"@type":"Organization","name":"Harvard Gazette","logo":"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2023\/12\/Harvard_Gazette_logo.svg"},"keywords":["cancer","cancer vaccine","dana-farber cancer institute","david j. mooney","donald ingber","harvard medical school","news hub","one harvard","research","science translational medicine","skin cancer","wyss institute","wyss institute for biologically inspired engineering"],"dateCreated":"2013-09-06T19:17:50Z","datePublished":"2013-09-06T19:17:50Z","dateModified":"2019-04-03T19:12:21Z"},"rendered":"<script type=\"application\/ld+json\" class=\"wp-parsely-metadata\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@type\":\"NewsArticle\",\"headline\":\"Cancer vaccine begins Phase I clinical trials\",\"url\":\"https:\\\/\\\/news.harvard.edu\\\/gazette\\\/story\\\/2013\\\/09\\\/cancer-vaccine-begins-phase-i-clinical-trials\\\/\",\"mainEntityOfPage\":{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/news.harvard.edu\\\/gazette\\\/story\\\/2013\\\/09\\\/cancer-vaccine-begins-phase-i-clinical-trials\\\/\"},\"thumbnailUrl\":\"https:\\\/\\\/news.harvard.edu\\\/wp-content\\\/uploads\\\/2013\\\/09\\\/cancervaccine605.jpg?w=150\",\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/news.harvard.edu\\\/wp-content\\\/uploads\\\/2013\\\/09\\\/cancervaccine605.jpg\"},\"articleSection\":\"Health\",\"author\":[{\"@type\":\"Person\",\"name\":\"harvardgazette\"}],\"creator\":[\"harvardgazette\"],\"publisher\":{\"@type\":\"Organization\",\"name\":\"Harvard Gazette\",\"logo\":\"https:\\\/\\\/news.harvard.edu\\\/gazette\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Harvard_Gazette_logo.svg\"},\"keywords\":[\"cancer\",\"cancer vaccine\",\"dana-farber cancer institute\",\"david j. mooney\",\"donald ingber\",\"harvard medical school\",\"news hub\",\"one harvard\",\"research\",\"science translational medicine\",\"skin cancer\",\"wyss institute\",\"wyss institute for biologically inspired engineering\"],\"dateCreated\":\"2013-09-06T19:17:50Z\",\"datePublished\":\"2013-09-06T19:17:50Z\",\"dateModified\":\"2019-04-03T19:12:21Z\"}<\/script>","tracker_url":"https:\/\/cdn.parsely.com\/keys\/news.harvard.edu\/p.js"},"jetpack_featured_media_url":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2013\/09\/cancervaccine605.jpg","has_blocks":true,"block_data":{"0":{"blockName":"harvard-gazette\/article-header","attrs":{"blockColorPalette":"","coloredHeading":"","creditText":"The Wyss Institute","displayDetails":"","displayTitle":"","categoryId":39644,"mediaAlt":"","mediaCaption":"","mediaId":"","mediaSize":"","mediaType":"video","mediaUrl":"https:\/\/www.youtube.com\/embed\/VsNmSSLBXs8","poster":"","title":"Cancer vaccine begins Phase I clinical trials","subheading":"Designed to target skin cancer, implantable vaccine opens door to treating many cancers, inflammatory diseases","centeredImage":true,"className":"is-style-full-width-text-below","isAmbient":false,"backgroundFixed":false,"backgroundTone":"light","coloredBackground":false,"displayOverlay":true,"fadeInText":false,"mediaHeight":0,"mediaLength":"","mediaPosition":"","mediaWidth":0,"posterText":"","titleAbove":false,"useUncroppedImage":false,"lock":[],"metadata":[]},"innerBlocks":[],"innerHTML":"<figure class=\"wp-block-video\">\r\nhttps:\/\/www.youtube.com\/embed\/VsNmSSLBXs8\r\n<figcaption class=\"wp-element-caption\"><p class=\"wp-element-caption--credit\">The Wyss Institute<\/p><\/figcaption><\/figure>\n","innerContent":["<figure class=\"wp-block-video\">\r\nhttps:\/\/www.youtube.com\/embed\/VsNmSSLBXs8\r\n<figcaption class=\"wp-element-caption\"><p class=\"wp-element-caption--credit\">The Wyss Institute<\/p><\/figcaption><\/figure>\n"],"rendered":"<header\n\tclass=\"wp-block-harvard-gazette-article-header alignfull article-header is-style-full-width-text-below centered-image\"\n\tstyle=\" \"\n>\n\t<figure class=\"wp-block-video\">\r\nhttps:\/\/www.youtube.com\/embed\/VsNmSSLBXs8\r\n<figcaption class=\"wp-element-caption\"><p class=\"wp-element-caption--credit\">The Wyss Institute<\/p><\/figcaption><\/figure>\n\n\t<div class=\"article-header__content\">\n\t\t\t<a\n\t\t\tclass=\"article-header__category\"\n\t\t\thref=\"https:\/\/news.harvard.edu\/gazette\/section\/health\/\"\n\t\t>\n\t\t\tHealth\t\t<\/a>\n\t\t\n\t\t<h1 class=\"article-header__title wp-block-heading \">\n\t\tCancer vaccine begins Phase I clinical trials\t<\/h1>\n\n\t\n\t\t\t<\/div>\n\t\t\n\t<div class=\"article-header__meta\">\n\t\t<div class=\"wp-block-post-author\">\n\t\t\t<address class=\"wp-block-post-author__content\">\n\t\t\t\t\t<p class=\"author wp-block-post-author__name\">\n\t\tDan Ferber\t<\/p>\n\t\t\t<p class=\"wp-block-post-author__byline\">\n\t\t\tWyss Institute Communications\t\t<\/p>\n\t\t\t\t\t<\/address>\n\t\t<\/div>\n\n\t\t<time class=\"article-header__date\" datetime=\"2013-09-06\">\n\t\t\tSeptember 6, 2013\t\t<\/time>\n\n\t\t<span class=\"article-header__reading-time\">\n\t\t\t4 min read\t\t<\/span>\n\t<\/div>\n\n\t\n\t\t\t<h2 class=\"article-header__subheading wp-block-heading\">\n\t\t\tDesigned to target skin cancer, implantable vaccine opens door to treating many cancers, inflammatory diseases\t\t<\/h2>\n\t\t\n<\/header>\n"},"2":{"blockName":"core\/group","attrs":{"templateLock":false,"metadata":{"name":"Article content"},"align":"wide","layout":{"type":"constrained","justifyContent":"center"},"tagName":"div","lock":[],"className":"","style":[],"backgroundColor":"","textColor":"","gradient":"","fontSize":"","fontFamily":"","borderColor":"","ariaLabel":"","anchor":""},"innerBlocks":[{"blockName":"core\/freeform","attrs":{"content":"","lock":[],"metadata":[]},"innerBlocks":[],"innerHTML":"\n\t\t<p>A cross-disciplinary team of Harvard scientists, engineers, and clinicians announced today that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer.<\/p>\n<p>The effort is the fruit of a new model of translational research being pursued at <a href=\"http:\/\/wyss.harvard.edu\/\">the Wyss Institute for Biologically Inspired Engineering at Harvard University<\/a> that integrates the latest cancer research with bioinspired technology development. It was led by Wyss core faculty member <a href=\"http:\/\/www.seas.harvard.edu\/directory\/mooneyd\">David J. Mooney<\/a>, who is also the Robert P. Pinkas Family Professor of Bioengineering at the <a href=\"http:\/\/www.seas.harvard.edu\/\">Harvard School of Engineering and Applied Sciences<\/a> (SEAS), and Wyss Institute associate faculty member Glenn Dranoff, who is co-leader of Dana-Farber Cancer Institute\u2019s Cancer Vaccine Center.<\/p>\n<p>Most therapeutic cancer vaccines available require doctors to first remove the patient\u2019s immune cells, then reprogram them and reintroduce them back into the body. The new approach, which was first reported to eliminate tumors in mice in <a href=\"http:\/\/stm.sciencemag.org\/\">Science Translational Medicine<\/a> in 2009, instead uses a disk-like sponge about the size of a fingernail that is made from FDA-approved polymers. The sponge is implanted under the skin, and is designed to recruit and reprogram a patient\u2019s own immune cells \u201con site,\u201d instructing them to travel through the body, home in on cancer cells, then kill them.<\/p>\n<p>The technology was initially designed to target cancerous cells in skin, but might have application to other cancers. In the preclinical study reported in Science Translational Medicine, 50 percent of mice treated with two doses of the vaccine \u2014 mice that would have otherwise died from melanoma within about 25 days \u2014 showed complete tumor regression.<\/p>\n<p>\u201cOur vaccine was made possible by combining a wide range of biomedical expertise that thrives in Boston and Cambridge,\u201d said Mooney, who specializes in the design of biomaterials for tissue engineering and drug delivery. \u201cIt reflects the bioinspired engineering savvy and technology development focus of engineers and scientists at the Wyss Institute and Harvard SEAS, as well as the immunological and clinical expertise of the researchers and clinicians at <a href=\"http:\/\/www.dana-farber.org\/\">Dana-Farber<\/a> and <a href=\"http:\/\/hms.harvard.edu\/\">Harvard Medical School<\/a>.\u201d<\/p>\n<p>\u201cThis is expected to be the first of many new innovative therapies made possible by the Wyss Institute\u2019s collaborative model of translational research that will enter human clinical trials,\u201d said Wyss\u2019 founding director, Don Ingber of <a href=\"http:\/\/www.childrenshospital.org\/\">Children\u2019s Hospital Boston<\/a>, who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and a professor of bioengineering at SEAS. \u201cIt validates our approach, which strives to move technologies into the clinical space much faster than would be possible in a traditional academic environment. It\u2019s enormously gratifying to see one of our first technologies take this giant leap forward.\u201d<\/p>\n<p>The Wyss Institute comprises a consortium of researchers, engineers, clinicians, and staff with industrial and business development experience from the Wyss Institute and nine other collaborating institutions in Greater Boston.<\/p>\n<p>\u201cIt is rare to get a new technology tested in the laboratory and moved into human clinical trials so quickly,\u201d said Dranoff, who is also a Professor of Medicine at Harvard Medical School, and leader of the Dana-Farber\/Harvard Cancer Center program in cancer immunology. \u201cWe\u2019re beyond thrilled with the momentum, and excited about its potential.\u201d<\/p>\n<p>The goal of the Phase I study, which is expected to conclude in 2015, is to assess the safety of the vaccine in humans.<\/p>\n<p>The cancer vaccine work has received support from the Wyss Institute, Dana-Farber, and the National Institutes of Health. In addition to Mooney, Dranoff, and Hodi, other collaborators include Wyss senior staff scientist Edward Doherty, Wyss staff scientist Omar Ali, Jerry Ritz, director of the Cell Processing Laboratory at Dana-Farber, Sara Russell, and Charles Yoon, surgeons at Dana-Farber, and other clinical research team members based at Dana-Farber.<\/p>\n<p><a href=\"http:\/\/wyss.harvard.edu\/viewpressrelease\/122\">To learn more.<\/a><\/p>\n","innerContent":["\n\t\t<p>A cross-disciplinary team of Harvard scientists, engineers, and clinicians announced today that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer.<\/p>\n<p>The effort is the fruit of a new model of translational research being pursued at <a href=\"http:\/\/wyss.harvard.edu\/\">the Wyss Institute for Biologically Inspired Engineering at Harvard University<\/a> that integrates the latest cancer research with bioinspired technology development. It was led by Wyss core faculty member <a href=\"http:\/\/www.seas.harvard.edu\/directory\/mooneyd\">David J. Mooney<\/a>, who is also the Robert P. Pinkas Family Professor of Bioengineering at the <a href=\"http:\/\/www.seas.harvard.edu\/\">Harvard School of Engineering and Applied Sciences<\/a> (SEAS), and Wyss Institute associate faculty member Glenn Dranoff, who is co-leader of Dana-Farber Cancer Institute\u2019s Cancer Vaccine Center.<\/p>\n<p>Most therapeutic cancer vaccines available require doctors to first remove the patient\u2019s immune cells, then reprogram them and reintroduce them back into the body. The new approach, which was first reported to eliminate tumors in mice in <a href=\"http:\/\/stm.sciencemag.org\/\">Science Translational Medicine<\/a> in 2009, instead uses a disk-like sponge about the size of a fingernail that is made from FDA-approved polymers. The sponge is implanted under the skin, and is designed to recruit and reprogram a patient\u2019s own immune cells \u201con site,\u201d instructing them to travel through the body, home in on cancer cells, then kill them.<\/p>\n<p>The technology was initially designed to target cancerous cells in skin, but might have application to other cancers. In the preclinical study reported in Science Translational Medicine, 50 percent of mice treated with two doses of the vaccine \u2014 mice that would have otherwise died from melanoma within about 25 days \u2014 showed complete tumor regression.<\/p>\n<p>\u201cOur vaccine was made possible by combining a wide range of biomedical expertise that thrives in Boston and Cambridge,\u201d said Mooney, who specializes in the design of biomaterials for tissue engineering and drug delivery. \u201cIt reflects the bioinspired engineering savvy and technology development focus of engineers and scientists at the Wyss Institute and Harvard SEAS, as well as the immunological and clinical expertise of the researchers and clinicians at <a href=\"http:\/\/www.dana-farber.org\/\">Dana-Farber<\/a> and <a href=\"http:\/\/hms.harvard.edu\/\">Harvard Medical School<\/a>.\u201d<\/p>\n<p>\u201cThis is expected to be the first of many new innovative therapies made possible by the Wyss Institute\u2019s collaborative model of translational research that will enter human clinical trials,\u201d said Wyss\u2019 founding director, Don Ingber of <a href=\"http:\/\/www.childrenshospital.org\/\">Children\u2019s Hospital Boston<\/a>, who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and a professor of bioengineering at SEAS. \u201cIt validates our approach, which strives to move technologies into the clinical space much faster than would be possible in a traditional academic environment. It\u2019s enormously gratifying to see one of our first technologies take this giant leap forward.\u201d<\/p>\n<p>The Wyss Institute comprises a consortium of researchers, engineers, clinicians, and staff with industrial and business development experience from the Wyss Institute and nine other collaborating institutions in Greater Boston.<\/p>\n<p>\u201cIt is rare to get a new technology tested in the laboratory and moved into human clinical trials so quickly,\u201d said Dranoff, who is also a Professor of Medicine at Harvard Medical School, and leader of the Dana-Farber\/Harvard Cancer Center program in cancer immunology. \u201cWe\u2019re beyond thrilled with the momentum, and excited about its potential.\u201d<\/p>\n<p>The goal of the Phase I study, which is expected to conclude in 2015, is to assess the safety of the vaccine in humans.<\/p>\n<p>The cancer vaccine work has received support from the Wyss Institute, Dana-Farber, and the National Institutes of Health. In addition to Mooney, Dranoff, and Hodi, other collaborators include Wyss senior staff scientist Edward Doherty, Wyss staff scientist Omar Ali, Jerry Ritz, director of the Cell Processing Laboratory at Dana-Farber, Sara Russell, and Charles Yoon, surgeons at Dana-Farber, and other clinical research team members based at Dana-Farber.<\/p>\n<p><a href=\"http:\/\/wyss.harvard.edu\/viewpressrelease\/122\">To learn more.<\/a><\/p>\n"],"rendered":"\n\t\t<p>A cross-disciplinary team of Harvard scientists, engineers, and clinicians announced today that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer.<\/p>\n<p>The effort is the fruit of a new model of translational research being pursued at <a href=\"http:\/\/wyss.harvard.edu\/\">the Wyss Institute for Biologically Inspired Engineering at Harvard University<\/a> that integrates the latest cancer research with bioinspired technology development. It was led by Wyss core faculty member <a href=\"http:\/\/www.seas.harvard.edu\/directory\/mooneyd\">David J. Mooney<\/a>, who is also the Robert P. Pinkas Family Professor of Bioengineering at the <a href=\"http:\/\/www.seas.harvard.edu\/\">Harvard School of Engineering and Applied Sciences<\/a> (SEAS), and Wyss Institute associate faculty member Glenn Dranoff, who is co-leader of Dana-Farber Cancer Institute\u2019s Cancer Vaccine Center.<\/p>\n<p>Most therapeutic cancer vaccines available require doctors to first remove the patient\u2019s immune cells, then reprogram them and reintroduce them back into the body. The new approach, which was first reported to eliminate tumors in mice in <a href=\"http:\/\/stm.sciencemag.org\/\">Science Translational Medicine<\/a> in 2009, instead uses a disk-like sponge about the size of a fingernail that is made from FDA-approved polymers. The sponge is implanted under the skin, and is designed to recruit and reprogram a patient\u2019s own immune cells \u201con site,\u201d instructing them to travel through the body, home in on cancer cells, then kill them.<\/p>\n<p>The technology was initially designed to target cancerous cells in skin, but might have application to other cancers. In the preclinical study reported in Science Translational Medicine, 50 percent of mice treated with two doses of the vaccine \u2014 mice that would have otherwise died from melanoma within about 25 days \u2014 showed complete tumor regression.<\/p>\n<p>\u201cOur vaccine was made possible by combining a wide range of biomedical expertise that thrives in Boston and Cambridge,\u201d said Mooney, who specializes in the design of biomaterials for tissue engineering and drug delivery. \u201cIt reflects the bioinspired engineering savvy and technology development focus of engineers and scientists at the Wyss Institute and Harvard SEAS, as well as the immunological and clinical expertise of the researchers and clinicians at <a href=\"http:\/\/www.dana-farber.org\/\">Dana-Farber<\/a> and <a href=\"http:\/\/hms.harvard.edu\/\">Harvard Medical School<\/a>.\u201d<\/p>\n<p>\u201cThis is expected to be the first of many new innovative therapies made possible by the Wyss Institute\u2019s collaborative model of translational research that will enter human clinical trials,\u201d said Wyss\u2019 founding director, Don Ingber of <a href=\"http:\/\/www.childrenshospital.org\/\">Children\u2019s Hospital Boston<\/a>, who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and a professor of bioengineering at SEAS. \u201cIt validates our approach, which strives to move technologies into the clinical space much faster than would be possible in a traditional academic environment. It\u2019s enormously gratifying to see one of our first technologies take this giant leap forward.\u201d<\/p>\n<p>The Wyss Institute comprises a consortium of researchers, engineers, clinicians, and staff with industrial and business development experience from the Wyss Institute and nine other collaborating institutions in Greater Boston.<\/p>\n<p>\u201cIt is rare to get a new technology tested in the laboratory and moved into human clinical trials so quickly,\u201d said Dranoff, who is also a Professor of Medicine at Harvard Medical School, and leader of the Dana-Farber\/Harvard Cancer Center program in cancer immunology. \u201cWe\u2019re beyond thrilled with the momentum, and excited about its potential.\u201d<\/p>\n<p>The goal of the Phase I study, which is expected to conclude in 2015, is to assess the safety of the vaccine in humans.<\/p>\n<p>The cancer vaccine work has received support from the Wyss Institute, Dana-Farber, and the National Institutes of Health. In addition to Mooney, Dranoff, and Hodi, other collaborators include Wyss senior staff scientist Edward Doherty, Wyss staff scientist Omar Ali, Jerry Ritz, director of the Cell Processing Laboratory at Dana-Farber, Sara Russell, and Charles Yoon, surgeons at Dana-Farber, and other clinical research team members based at Dana-Farber.<\/p>\n<p><a href=\"http:\/\/wyss.harvard.edu\/viewpressrelease\/122\">To learn more.<\/a><\/p>\n"}],"innerHTML":"\n<div class=\"wp-block-group alignwide\">\n\n\n\n<\/div>\n","innerContent":["\n<div class=\"wp-block-group alignwide\">\n\n","\n\n<\/div>\n"],"rendered":"\n<div class=\"wp-block-group alignwide has-global-padding is-content-justification-center is-layout-constrained wp-block-group-is-layout-constrained\">\n\n\n\t\t<p>A cross-disciplinary team of Harvard scientists, engineers, and clinicians announced today that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer.<\/p>\n<p>The effort is the fruit of a new model of translational research being pursued at <a href=\"http:\/\/wyss.harvard.edu\/\">the Wyss Institute for Biologically Inspired Engineering at Harvard University<\/a> that integrates the latest cancer research with bioinspired technology development. It was led by Wyss core faculty member <a href=\"http:\/\/www.seas.harvard.edu\/directory\/mooneyd\">David J. Mooney<\/a>, who is also the Robert P. Pinkas Family Professor of Bioengineering at the <a href=\"http:\/\/www.seas.harvard.edu\/\">Harvard School of Engineering and Applied Sciences<\/a> (SEAS), and Wyss Institute associate faculty member Glenn Dranoff, who is co-leader of Dana-Farber Cancer Institute\u2019s Cancer Vaccine Center.<\/p>\n<p>Most therapeutic cancer vaccines available require doctors to first remove the patient\u2019s immune cells, then reprogram them and reintroduce them back into the body. The new approach, which was first reported to eliminate tumors in mice in <a href=\"http:\/\/stm.sciencemag.org\/\">Science Translational Medicine<\/a> in 2009, instead uses a disk-like sponge about the size of a fingernail that is made from FDA-approved polymers. The sponge is implanted under the skin, and is designed to recruit and reprogram a patient\u2019s own immune cells \u201con site,\u201d instructing them to travel through the body, home in on cancer cells, then kill them.<\/p>\n<p>The technology was initially designed to target cancerous cells in skin, but might have application to other cancers. In the preclinical study reported in Science Translational Medicine, 50 percent of mice treated with two doses of the vaccine \u2014 mice that would have otherwise died from melanoma within about 25 days \u2014 showed complete tumor regression.<\/p>\n<p>\u201cOur vaccine was made possible by combining a wide range of biomedical expertise that thrives in Boston and Cambridge,\u201d said Mooney, who specializes in the design of biomaterials for tissue engineering and drug delivery. \u201cIt reflects the bioinspired engineering savvy and technology development focus of engineers and scientists at the Wyss Institute and Harvard SEAS, as well as the immunological and clinical expertise of the researchers and clinicians at <a href=\"http:\/\/www.dana-farber.org\/\">Dana-Farber<\/a> and <a href=\"http:\/\/hms.harvard.edu\/\">Harvard Medical School<\/a>.\u201d<\/p>\n<p>\u201cThis is expected to be the first of many new innovative therapies made possible by the Wyss Institute\u2019s collaborative model of translational research that will enter human clinical trials,\u201d said Wyss\u2019 founding director, Don Ingber of <a href=\"http:\/\/www.childrenshospital.org\/\">Children\u2019s Hospital Boston<\/a>, who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and a professor of bioengineering at SEAS. \u201cIt validates our approach, which strives to move technologies into the clinical space much faster than would be possible in a traditional academic environment. It\u2019s enormously gratifying to see one of our first technologies take this giant leap forward.\u201d<\/p>\n<p>The Wyss Institute comprises a consortium of researchers, engineers, clinicians, and staff with industrial and business development experience from the Wyss Institute and nine other collaborating institutions in Greater Boston.<\/p>\n<p>\u201cIt is rare to get a new technology tested in the laboratory and moved into human clinical trials so quickly,\u201d said Dranoff, who is also a Professor of Medicine at Harvard Medical School, and leader of the Dana-Farber\/Harvard Cancer Center program in cancer immunology. \u201cWe\u2019re beyond thrilled with the momentum, and excited about its potential.\u201d<\/p>\n<p>The goal of the Phase I study, which is expected to conclude in 2015, is to assess the safety of the vaccine in humans.<\/p>\n<p>The cancer vaccine work has received support from the Wyss Institute, Dana-Farber, and the National Institutes of Health. In addition to Mooney, Dranoff, and Hodi, other collaborators include Wyss senior staff scientist Edward Doherty, Wyss staff scientist Omar Ali, Jerry Ritz, director of the Cell Processing Laboratory at Dana-Farber, Sara Russell, and Charles Yoon, surgeons at Dana-Farber, and other clinical research team members based at Dana-Farber.<\/p>\n<p><a href=\"http:\/\/wyss.harvard.edu\/viewpressrelease\/122\">To learn more.<\/a><\/p>\n\n\n<\/div>\n"}},"jetpack-related-posts":[{"id":240807,"url":"https:\/\/news.harvard.edu\/gazette\/story\/2018\/03\/cancer-treatment-gets-boost-from-licensing-agreement\/","url_meta":{"origin":145737,"position":0},"title":"Novel cancer treatment gets major boost","author":"harvardgazette","date":"March 21, 2018","format":false,"excerpt":"The Wyss Institute and Harvard John A. Paulson School of Engineering and Applied Sciences announced Novartis will have access to commercially develop their therapeutic, biomaterial-based cancer vaccine technology.","rel":"","context":"In &quot;Science &amp; Tech&quot;","block_context":{"text":"Science &amp; Tech","link":"https:\/\/news.harvard.edu\/gazette\/section\/science-technology\/"},"img":{"alt_text":"researcher holds a device","src":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/03\/researcher-holding-cancer-vaccine-scaffold_2500.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/03\/researcher-holding-cancer-vaccine-scaffold_2500.jpg?resize=350%2C200 1x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/03\/researcher-holding-cancer-vaccine-scaffold_2500.jpg?resize=525%2C300 1.5x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/03\/researcher-holding-cancer-vaccine-scaffold_2500.jpg?resize=700%2C400 2x"},"classes":[]},{"id":139274,"url":"https:\/\/news.harvard.edu\/gazette\/story\/2013\/05\/wyss-gift\/","url_meta":{"origin":145737,"position":1},"title":"Hansj\u00f6rg Wyss doubles his gift","author":"harvardgazette","date":"May 21, 2013","format":false,"excerpt":"Founding donor Hansj\u00f6rg Wyss doubled his gift to Harvard\u2019s Wyss Institute for Biologically Inspired Engineering from $125 million to $250 million to the University to further advance the institute\u2019s pioneering work.","rel":"","context":"In &quot;Campus &amp; Community&quot;","block_context":{"text":"Campus &amp; Community","link":"https:\/\/news.harvard.edu\/gazette\/section\/campus-community\/"},"img":{"alt_text":"","src":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2013\/05\/hansjorg-wyss-201211191_605.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2013\/05\/hansjorg-wyss-201211191_605.jpg?resize=350%2C200 1x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2013\/05\/hansjorg-wyss-201211191_605.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":299561,"url":"https:\/\/news.harvard.edu\/gazette\/story\/2020\/03\/nih-funded-i3-center-formed-to-advance-cancer-immunotherapy\/","url_meta":{"origin":145737,"position":2},"title":"i3 Center formed for advancing cancer immunotherapy","author":"harvardgazette","date":"March 6, 2020","format":false,"excerpt":"Harvard\u2019s Wyss Institute will collaborate with other institutions to form the i3 Center where cancer immunologists and biological engineers will develop new biomaterials-based approaches to enable anti-cancer immune-therapies for therapy-resistant cancers.","rel":"","context":"In &quot;Science &amp; Tech&quot;","block_context":{"text":"Science &amp; Tech","link":"https:\/\/news.harvard.edu\/gazette\/section\/science-technology\/"},"img":{"alt_text":"Illustration of cancer cells.","src":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2020\/03\/SM_shutterstock_1408531508.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2020\/03\/SM_shutterstock_1408531508.jpg?resize=350%2C200 1x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2020\/03\/SM_shutterstock_1408531508.jpg?resize=525%2C300 1.5x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2020\/03\/SM_shutterstock_1408531508.jpg?resize=700%2C400 2x"},"classes":[]},{"id":144681,"url":"https:\/\/news.harvard.edu\/gazette\/story\/2013\/08\/vaccine-works-on-hard-to-treat-leukemia\/","url_meta":{"origin":145737,"position":3},"title":"Vaccine works on hard-to-treat leukemia\u2028","author":"harvardgazette","date":"August 6, 2013","format":false,"excerpt":"Scientists at Harvard-affiliated Dana-Farber Cancer Institute observed a strong and selective immune response in some patients who received several doses of a \u201cpersonalized\u201d tumor vaccine composed of their own inactivated leukemia cells combined with an immune stimulant.","rel":"","context":"In &quot;Health&quot;","block_context":{"text":"Health","link":"https:\/\/news.harvard.edu\/gazette\/section\/health\/"},"img":{"alt_text":"","src":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2013\/08\/chronic_lymphocytic_leukemia_-_high_mag.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2013\/08\/chronic_lymphocytic_leukemia_-_high_mag.jpg?resize=350%2C200 1x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2013\/08\/chronic_lymphocytic_leukemia_-_high_mag.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":316430,"url":"https:\/\/news.harvard.edu\/gazette\/story\/2020\/11\/new-technique-could-treat-cancer-metastasis\/","url_meta":{"origin":145737,"position":4},"title":"Turning the problem of cancer metastasis into an opportunity","author":"Lian Parsons","date":"November 16, 2020","format":false,"excerpt":"Delivering immune-stimulating nanoparticles to the lungs via red blood cells halts tumor growth in mice.","rel":"","context":"In &quot;Health&quot;","block_context":{"text":"Health","link":"https:\/\/news.harvard.edu\/gazette\/section\/health\/"},"img":{"alt_text":"Red blood cells.","src":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2020\/11\/RBC-Spleen-Activation-001_2500.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2020\/11\/RBC-Spleen-Activation-001_2500.jpg?resize=350%2C200 1x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2020\/11\/RBC-Spleen-Activation-001_2500.jpg?resize=525%2C300 1.5x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2020\/11\/RBC-Spleen-Activation-001_2500.jpg?resize=700%2C400 2x"},"classes":[]},{"id":310771,"url":"https:\/\/news.harvard.edu\/gazette\/story\/2020\/08\/vaccine-strategy-could-aid-in-covid-19-immunization\/","url_meta":{"origin":145737,"position":5},"title":"Putting a crown on OMNIVAX","author":"Lian Parsons","date":"August 19, 2020","format":false,"excerpt":"A biomaterials-based infection vaccine strategy shows first promise in eliciting immunity against SARS-CoV-2 and could be applied broadly to stave off infectious disease.","rel":"","context":"In &quot;Science &amp; Tech&quot;","block_context":{"text":"Science &amp; Tech","link":"https:\/\/news.harvard.edu\/gazette\/section\/science-technology\/"},"img":{"alt_text":"Omnivax protein.","src":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2020\/08\/OMNIVAX-COVIDspikeprotein_2500.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2020\/08\/OMNIVAX-COVIDspikeprotein_2500.jpg?resize=350%2C200 1x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2020\/08\/OMNIVAX-COVIDspikeprotein_2500.jpg?resize=525%2C300 1.5x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2020\/08\/OMNIVAX-COVIDspikeprotein_2500.jpg?resize=700%2C400 2x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/posts\/145737","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/users\/105622744"}],"replies":[{"embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/comments?post=145737"}],"version-history":[{"count":3,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/posts\/145737\/revisions"}],"predecessor-version":[{"id":270221,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/posts\/145737\/revisions\/270221"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/media\/146093"}],"wp:attachment":[{"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/media?parent=145737"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/categories?post=145737"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/tags?post=145737"},{"taxonomy":"format","embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/gazette-formats?post=145737"},{"taxonomy":"series","embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/series?post=145737"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}